Teva Pharmaceutical Industries ADR (TEVA)

$19.96 -0.05 (-0.25%)
Market Cap 22.95B
Revenue (ttm) 16.54B
Net Income (ttm) -1.64B
EPS (ttm) N/A
PE Ratio 8.02
Forward PE 8.18
Profit Margin -9.91%
Debt to Equity Ratio 2.52
Volume 9,328,201
Avg Vol 11,508,060
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 73%
Beta 0.71
Analysts Strong Sell
Price Target $24.25

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 914 8213
Address:
124 Dvora HaNevi’a St., Tel Aviv, Israel
Thespartantrades
Thespartantrades Oct. 7 at 9:49 AM
$CART $ERIC $FLNC $TEVA Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 9:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $20.20 Contracts: $TEVA January 15, 2027 $22 Calls Scale in: $3.02- $3.70 Scale out: $4.70-$6.05 Can Easily Capture: 60% ROI Blended DTE: 466 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
NNJAWINLIVE
NNJAWINLIVE Oct. 7 at 1:05 AM
$TEVA COVER YOUR SHORTS 30 THEN 70S NEW ALL TIME HIGH!
0 · Reply
Komahachi
Komahachi Oct. 6 at 10:32 PM
$TEVA Go Druck!!! Saw this floating around yahoo news this afternoon...Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters (TEVA now his #2 portfolio position) - Q3 2024: 1,427,950 shares purchased - Q4 2024: 7,569,450 shares purchased - Q1 2025: 5,882,350 shares purchased - Q2 2025: 1,089,185 shares purchased ** Stock position is valued at over $319ML (15,968,935 total shares held) The data jives with latest data on Nasdaq activity page as well - no filing changes so he ain't sold it yet! https://www.nasdaq.com/market-activity/stocks/teva/institutional-holdings?page=2&rows_per_page=10
0 · Reply
Thespartantrade
Thespartantrade Oct. 6 at 10:13 PM
$FLNC $TEVA $ENVX $SLB Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
1 · Reply
NNJAWINLIVE
NNJAWINLIVE Oct. 6 at 5:23 PM
$TEVA going to VIVA!! 30
1 · Reply
NoTradeAnymore
NoTradeAnymore Oct. 6 at 2:52 PM
$TEVA who gives a sht about this stock? AI is making millionaires every single day, who in the world will look into TEVA...really?
1 · Reply
ProfitMafia
ProfitMafia Oct. 6 at 2:32 PM
$TEVA 21 call 10/10 @ 0.16 Target #1: 20.40 Strict stop loss: 19.90
0 · Reply
ProfitMafia
ProfitMafia Oct. 6 at 2:25 PM
$TEVA 21 call 10/10 @ 0.15… move
0 · Reply
Quantumup
Quantumup Oct. 6 at 1:42 PM
Truist reiterated $CORT Buy-$135 and said that is sees Asymmetric Risk/Reward With Downside Protection Even Under Worst-Case Scenario $TEVA $ABBV Truist additionally said: We hosted CORT CFO for NDR with key takeaways. Focus is on two upcoming catalysts: CORT vs TEVA decision (due any day) and relacorilant PDUFA by Dec 30. As we layout 4 scenarios with stock implications, we see asymmetric risk/reward given downside protection even on the worst-case scenario (highly unlikely): rela CRL and Korlym loss to TEVA, given accelerating Korlym revenue growth despite availability of TEVA generic since Jan 2024. Upside is significant as IP win could see Korlym growth further accelerate and rela approval could further expand TAM. Oncology is a growing focus and ALS is also in the cross-hairs with Ph3 due to start soon. Reit $135PT & BUY Rating.
0 · Reply
Latest News on TEVA
Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 11 days ago

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 4:30 PM EDT - 11 days ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Sep 25, 2025, 11:42 AM EDT - 11 days ago

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 24, 2025, 7:23 AM EDT - 12 days ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited - Special Call

Sep 22, 2025, 2:53 PM EDT - 14 days ago

Teva Pharmaceutical Industries Limited - Special Call

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 20, 2025, 10:15 PM EDT - 16 days ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 17, 2025, 8:00 AM EDT - 19 days ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 16, 2025, 4:30 PM EDT - 20 days ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:57 PM EDT - 27 days ago

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Colorado must face Teva's lawsuit over free allergy pen law

Sep 5, 2025, 3:57 PM EDT - 4 weeks ago

Colorado must face Teva's lawsuit over free allergy pen law

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Sep 2, 2025, 4:30 PM EDT - 4 weeks ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

US FDA approves Teva Pharmaceuticals' generic obesity drug

Aug 28, 2025, 9:17 AM EDT - 5 weeks ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

Aug 28, 2025, 1:43 AM EDT - 5 weeks ago

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

Aug 19, 2025, 9:00 AM EDT - 6 weeks ago

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

US FDA approves Teva's Ajovy for migraine prevention in children

Aug 5, 2025, 6:16 PM EDT - 2 months ago

US FDA approves Teva's Ajovy for migraine prevention in children

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Jul 31, 2025, 3:27 PM EDT - 2 months ago

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Teva CEO: Our supply chain puts us in a strong position

Jul 30, 2025, 12:40 PM EDT - 2 months ago

Teva CEO: Our supply chain puts us in a strong position

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 11:50 AM EDT - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

Teva Pharm Q2 profit beats estimates as branded drugs gain

Jul 30, 2025, 7:21 AM EDT - 2 months ago

Teva Pharm Q2 profit beats estimates as branded drugs gain

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Jul 29, 2025, 2:44 PM EDT - 2 months ago

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Releases Q2 2025 Aide Memoire

Jun 26, 2025, 4:30 PM EDT - 3 months ago

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Jun 25, 2025, 4:30 PM EDT - 3 months ago

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Jun 23, 2025, 3:00 AM EDT - 3 months ago

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Jun 16, 2025, 9:03 AM EDT - 4 months ago

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 10, 2025, 11:46 AM EDT - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

Jun 5, 2025, 7:09 AM EDT - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Jun 3, 2025, 5:30 PM EDT - 4 months ago

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Jun 3, 2025, 7:16 AM EDT - 4 months ago

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025, 9:05 PM EDT - 4 months ago

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

May 30, 2025, 9:00 PM EDT - 4 months ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 29, 2025, 8:00 AM EDT - 4 months ago

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27, 2025, 5:30 PM EDT - 4 months ago

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27, 2025, 4:30 PM EDT - 4 months ago

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Why Is Teva Stock Trading Higher On Tuesday?

May 27, 2025, 3:44 PM EDT - 4 months ago

Why Is Teva Stock Trading Higher On Tuesday?

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 27, 2025, 8:30 AM EDT - 4 months ago

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Why Investors Should Watch Teva Despite Regional Risks

May 23, 2025, 12:52 PM EDT - 4 months ago

Why Investors Should Watch Teva Despite Regional Risks

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 22, 2025, 1:56 PM EDT - 4 months ago

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

May 20, 2025, 5:22 PM EDT - 4 months ago

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

May 20, 2025, 4:30 PM EDT - 4 months ago

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

May 19, 2025, 4:52 AM EDT - 5 months ago

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

May 19, 2025, 4:52 AM EDT - 5 months ago

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

May 15, 2025, 6:12 PM EDT - 5 months ago

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

May 8, 2025, 11:33 AM EDT - 5 months ago

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

May 7, 2025, 1:01 PM EDT - 5 months ago

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

May 7, 2025, 12:13 PM EDT - 5 months ago

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties

May 7, 2025, 11:51 AM EDT - 5 months ago

Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties

Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript

May 7, 2025, 10:47 AM EDT - 5 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript

Teva Pharm first-quarter profit rise tops estimates

May 7, 2025, 7:30 AM EDT - 5 months ago

Teva Pharm first-quarter profit rise tops estimates

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

May 7, 2025, 7:00 AM EDT - 5 months ago

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

May 7, 2025, 7:00 AM EDT - 5 months ago

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

Thespartantrades
Thespartantrades Oct. 7 at 9:49 AM
$CART $ERIC $FLNC $TEVA Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 9:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $20.20 Contracts: $TEVA January 15, 2027 $22 Calls Scale in: $3.02- $3.70 Scale out: $4.70-$6.05 Can Easily Capture: 60% ROI Blended DTE: 466 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
NNJAWINLIVE
NNJAWINLIVE Oct. 7 at 1:05 AM
$TEVA COVER YOUR SHORTS 30 THEN 70S NEW ALL TIME HIGH!
0 · Reply
Komahachi
Komahachi Oct. 6 at 10:32 PM
$TEVA Go Druck!!! Saw this floating around yahoo news this afternoon...Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters (TEVA now his #2 portfolio position) - Q3 2024: 1,427,950 shares purchased - Q4 2024: 7,569,450 shares purchased - Q1 2025: 5,882,350 shares purchased - Q2 2025: 1,089,185 shares purchased ** Stock position is valued at over $319ML (15,968,935 total shares held) The data jives with latest data on Nasdaq activity page as well - no filing changes so he ain't sold it yet! https://www.nasdaq.com/market-activity/stocks/teva/institutional-holdings?page=2&rows_per_page=10
0 · Reply
Thespartantrade
Thespartantrade Oct. 6 at 10:13 PM
$FLNC $TEVA $ENVX $SLB Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
1 · Reply
NNJAWINLIVE
NNJAWINLIVE Oct. 6 at 5:23 PM
$TEVA going to VIVA!! 30
1 · Reply
NoTradeAnymore
NoTradeAnymore Oct. 6 at 2:52 PM
$TEVA who gives a sht about this stock? AI is making millionaires every single day, who in the world will look into TEVA...really?
1 · Reply
ProfitMafia
ProfitMafia Oct. 6 at 2:32 PM
$TEVA 21 call 10/10 @ 0.16 Target #1: 20.40 Strict stop loss: 19.90
0 · Reply
ProfitMafia
ProfitMafia Oct. 6 at 2:25 PM
$TEVA 21 call 10/10 @ 0.15… move
0 · Reply
Quantumup
Quantumup Oct. 6 at 1:42 PM
Truist reiterated $CORT Buy-$135 and said that is sees Asymmetric Risk/Reward With Downside Protection Even Under Worst-Case Scenario $TEVA $ABBV Truist additionally said: We hosted CORT CFO for NDR with key takeaways. Focus is on two upcoming catalysts: CORT vs TEVA decision (due any day) and relacorilant PDUFA by Dec 30. As we layout 4 scenarios with stock implications, we see asymmetric risk/reward given downside protection even on the worst-case scenario (highly unlikely): rela CRL and Korlym loss to TEVA, given accelerating Korlym revenue growth despite availability of TEVA generic since Jan 2024. Upside is significant as IP win could see Korlym growth further accelerate and rela approval could further expand TAM. Oncology is a growing focus and ALS is also in the cross-hairs with Ph3 due to start soon. Reit $135PT & BUY Rating.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 8:01 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $20.01 Contracts: $TEVA January 15, 2027 $22 Calls Scale in: $2.98- $3.64 Scale out: $4.64-$5.96 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 4 at 5:57 PM
$DUO $TEVA $LOT $ADUR Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
Hopewisper
Hopewisper Oct. 3 at 8:46 PM
$TEVA Guess who...
0 · Reply
Terrordomo80
Terrordomo80 Oct. 3 at 7:57 PM
$TEVA And thats exactly why its TEVA the turd! Great job today boys... youve accomplished nothing!!!
0 · Reply
Marcel_TG
Marcel_TG Oct. 3 at 7:42 PM
$PLUG I invest part of it in $TEVA
0 · Reply
Marcel_TG
Marcel_TG Oct. 3 at 7:38 PM
$TEVA
0 · Reply
Marcel_TG
Marcel_TG Oct. 3 at 7:38 PM
$TEVA
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 3 at 7:10 PM
$TEVA
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:00 PM
$TEVA $TME $IAG $ABT Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 4:52 PM
$TEVA: Unusual Options Activity Alerted CALL flow observed 4000x contracts at Strike price of $21 Exp on 10/17/2025 with Premium of $128K and showing BEARISH Sentiment
0 · Reply
NoTradeAnymore
NoTradeAnymore Oct. 3 at 4:29 PM
$TEVA the whole market is on fking fire ...and Teva is floating on its own sheeeet...where are the clowns screaming 30!!!! Lol
0 · Reply
premarketmaker
premarketmaker Oct. 3 at 2:08 PM
$TEVA $20.61 HOD/squeeze
0 · Reply